129 related articles for article (PubMed ID: 23111067)
1. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
Amaru Calzada A; Pedrini O; Finazzi G; Leoni F; Mascagni P; Introna M; Rambaldi A; Golay J;
Exp Hematol; 2013 Mar; 41(3):253-60.e2. PubMed ID: 23111067
[TBL] [Abstract][Full Text] [Related]
2. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
[TBL] [Abstract][Full Text] [Related]
3. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
[TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
5. Givinostat: an emerging treatment for polycythemia vera.
Chifotides HT; Bose P; Verstovsek S
Expert Opin Investig Drugs; 2020 Jun; 29(6):525-536. PubMed ID: 32693648
[TBL] [Abstract][Full Text] [Related]
6. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
7. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
[TBL] [Abstract][Full Text] [Related]
8. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
9. Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2
Zhou J; Guo C; Wu H; Li B; Zhou LL; Liang AB; Fu JF
BMC Cancer; 2021 Nov; 21(1):1213. PubMed ID: 34773997
[TBL] [Abstract][Full Text] [Related]
10. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Krämer OH; Knauer SK; Zimmermann D; Stauber RH; Heinzel T
Oncogene; 2008 Jan; 27(6):732-40. PubMed ID: 17653085
[TBL] [Abstract][Full Text] [Related]
12. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.
Abe M; Funakoshi-Tago M; Tago K; Kamishimoto J; Aizu-Yokota E; Sonoda Y; Kasahara T
Int Immunopharmacol; 2009 Jul; 9(7-8):870-7. PubMed ID: 19327411
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Guerini V; Barbui V; Spinelli O; Salvi A; Dellacasa C; Carobbio A; Introna M; Barbui T; Golay J; Rambaldi A
Leukemia; 2008 Apr; 22(4):740-7. PubMed ID: 18079739
[TBL] [Abstract][Full Text] [Related]
14. Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
Szymańska J; Smolewski P; Majchrzak A; Cebula-Obrzut B; Chojnowski K; Treliński J
Adv Clin Exp Med; 2015; 24(2):195-202. PubMed ID: 25931349
[TBL] [Abstract][Full Text] [Related]
15. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
Kubovcakova L; Lundberg P; Grisouard J; Hao-Shen H; Romanet V; Andraos R; Murakami M; Dirnhofer S; Wagner KU; Radimerski T; Skoda RC
Blood; 2013 Feb; 121(7):1188-99. PubMed ID: 23264594
[TBL] [Abstract][Full Text] [Related]
17. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in
Chen CC; You JY; Lung J; Huang CE; Chen YY; Leu YW; Ho HY; Li CP; Lu CH; Lee KD; Hsu CC; Gau JP
Haematologica; 2017 Mar; 102(3):509-518. PubMed ID: 28057739
[TBL] [Abstract][Full Text] [Related]
18. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
Petiti J; Rosso V; Lo Iacono M; Panuzzo C; Calabrese C; Signorino E; Pironi L; Cartellà A; Bracco E; Pergolizzi B; Beltramo T; Fava C; Cilloni D
J Cell Mol Med; 2019 Jun; 23(6):4349-4357. PubMed ID: 31033209
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
